article thumbnail

Re-examining antibodies' role in childhood allergies

Medical Xpress

The presence of food-specific IgA antibodies in the gut does not prevent peanut or egg allergies from developing in children, according to a Northwestern Medicine study published in Science Translational Medicine.

article thumbnail

Asthma Drug Xolair Wins FDA Approval as First Treatment for Multiple Food Allergies

XTalks

The class of IgE-mediated food allergies includes 160 foods, with peanuts, milk, eggs, wheat, soy and tree nuts being the most common ones. According to the Centers for Disease Control and Prevention (CDC), almost six percent of people in the US in 2021 had a food allergy. However, the treatment is restricted to peanut allergy.

Allergies 100
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Maternal Antibodies: How Allergies Can be Passed from Mothers to Children

XTalks

It has long been known that mothers greatly influence the development of the growing fetus by not only providing nutrients through the placenta, but also a growing list of biological elements including beneficial antibodies, gut bacteria and now, allergies. Related: Red Meat Allergy Test Gets FDA Clearance.

article thumbnail

Antibody treatment improves chronic food allergy symptoms in young adults, study finds

Medical Xpress

A weekly dose of dupilumab, a monoclonal antibody, led to a reduction of symptoms and tissue improvement in young adults and adolescents with eosinophilic esophagitis (EoE), according to a new study published in the New England Journal of Medicine.

article thumbnail

Monoclonal antibody could transform malaria prevention

Drug Discovery World

One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa. . The antibody was up to 88.2% The Phase II NIAID-USTTB trial evaluated a one-time, intravenous infusion of a monoclonal antibody called CIS43LS. .

article thumbnail

Large NIH clinical trial will test polyclonal antibody therapeutic for COVID-19

Scienmag

Credit: NIAID A Phase 2/3 trial to evaluate a new fully-human polyclonal antibody therapeutic targeted to SARS-CoV-2, called SAB-185, has begun enrolling non-hospitalized people with mild or moderate cases of COVID-19.

article thumbnail

US buys Lilly COVID antibody, as effectiveness questions remain

pharmaphorum

The US has said that patients will have no out-of-pocket costs for the medicine – echoing a promise by Lilly CEO Dave Ricks – although healthcare facilities may charge a fee for the product’s administration. . Our goal is to ensure that Lilly antibody treatments are available to patients who need them, no matter where they live. “As